PVCTProvectus BiopharmaceuticalsPVCT info
$0.09info0.00%24h
Global rank26779
Market cap$37.76M
Change 7d-28.00%
YTD Performance5.88%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Provectus Biopharmaceuticals (PVCT) Stock Overview

    Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

    PVCT Stock Information

    Symbol
    PVCT
    Address
    800 South Gay StreetKnoxville, TN 37929United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.provectusbio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    866 594 5999

    Provectus Biopharmaceuticals (PVCT) Price Chart

    -
    Value:-

    Provectus Biopharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.09
    N/A
    Market Cap
    $37.76M
    N/A
    Shares Outstanding
    419.52M
    N/A
    Employees
    4.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org